25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Corcept Therapeutics Incorporated
Buy, Hold or Sell?

Let's analyze Corcept together

I guess you are interested in Corcept Therapeutics Incorporated. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Corcept Therapeutics Incorporated. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Corcept Therapeutics Incorporated

I send you an email if I find something interesting about Corcept Therapeutics Incorporated.

1. Quick Overview

1.1. Quick analysis of Corcept (30 sec.)










1.2. What can you expect buying and holding a share of Corcept? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€5.84
Expected worth in 1 year
€7.46
How sure are you?
90.6%

+ What do you gain per year?

Total Gains per Share
€1.62
Return On Investment
3.3%

For what price can you sell your share?

Current Price per Share
€49.18
Expected price per share
€37.48 - €58.44
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Corcept (5 min.)




Live pricePrice per Share (EOD)
€49.18
Intrinsic Value Per Share
€21.80 - €25.69
Total Value Per Share
€27.65 - €31.54

2.2. Growth of Corcept (5 min.)




Is Corcept growing?

Current yearPrevious yearGrowGrow %
How rich?$638.8m$478.6m$93.7m16.4%

How much money is Corcept making?

Current yearPrevious yearGrowGrow %
Making money$36.9m$23.8m$13.1m35.6%
Net Profit Margin22.4%20.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Corcept (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#97 / 943

Most Revenue
#60 / 943

Most Profit
#38 / 943
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Corcept?

Welcome investor! Corcept's management wants to use your money to grow the business. In return you get a share of Corcept.

First you should know what it really means to hold a share of Corcept. And how you can make/lose money.

Speculation

The Price per Share of Corcept is €49.18. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Corcept.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Corcept, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €5.84. Based on the TTM, the Book Value Change Per Share is €0.41 per quarter. Based on the YOY, the Book Value Change Per Share is €0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Corcept.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.471.0%0.350.7%0.250.5%0.280.6%0.260.5%
Usd Book Value Change Per Share0.410.8%0.420.9%0.000.0%0.150.3%0.190.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.410.8%0.420.9%0.000.0%0.150.3%0.190.4%
Usd Price Per Share40.56-31.71-23.49-22.32-18.55-
Price to Earnings Ratio21.57-22.56-23.98-20.48-21.18-
Price-to-Total Gains Ratio99.77-75.20-55.49-63.05-65.43-
Price to Book Ratio6.65-5.79-5.27-4.96-6.90-
Price-to-Total Gains Ratio99.77-75.20-55.49-63.05-65.43-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share51.314412
Number of shares19
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.420.15
Usd Total Gains Per Share0.420.15
Gains per Quarter (19 shares)8.032.76
Gains per Year (19 shares)32.1311.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1032220111
20645402212
30968603323
4012911804434
5016115005545
6019318206656
7022521407767
8025724608878
9028927809989
1003213100110100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%32.00.00.0100.0%32.00.00.0100.0%
Book Value Change Per Share4.00.00.0100.0%10.02.00.083.3%17.03.00.085.0%29.03.00.090.6%29.03.00.090.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.032.00.0%0.00.032.00.0%
Total Gains per Share4.00.00.0100.0%10.02.00.083.3%17.03.00.085.0%29.03.00.090.6%29.03.00.090.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Corcept Therapeutics Incorporated compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3900.405-4%0.002+17712%0.139+180%0.183+113%
Book Value Per Share--5.8445.236+12%4.308+36%4.255+37%3.330+75%
Current Ratio--3.7004.708-21%5.462-32%7.376-50%6.589-44%
Debt To Asset Ratio--0.1850.175+6%0.175+6%0.127+46%0.145+28%
Debt To Equity Ratio--0.2280.212+7%0.215+6%0.148+53%0.180+27%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--3933231805.2003067518816.800+28%2292811616.150+72%2256112463.006+74%1861907658.216+111%
Eps--0.4510.338+33%0.241+87%0.264+71%0.247+83%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--5.3874.870+11%5.063+6%5.203+4%5.543-3%
Free Cash Flow Per Share--0.6600.326+103%0.349+89%0.324+104%0.324+104%
Free Cash Flow To Equity Per Share--0.4670.273+71%0.322+45%0.164+185%0.164+185%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--25.694--------
Intrinsic Value_10Y_min--21.802--------
Intrinsic Value_1Y_max--1.493--------
Intrinsic Value_1Y_min--1.466--------
Intrinsic Value_3Y_max--5.311--------
Intrinsic Value_3Y_min--5.053--------
Intrinsic Value_5Y_max--10.122--------
Intrinsic Value_5Y_min--9.324--------
Market Cap5152834500.000+21%4072604250.0003184112250.000+28%2389898973.750+70%2326108392.366+75%1916432112.416+113%
Net Profit Margin--0.2590.224+15%0.200+29%0.265-2%0.321-19%
Operating Margin----0%0.118-100%0.229-100%0.269-100%
Operating Ratio--0.7600.789-4%0.798-5%0.722+5%0.661+15%
Pb Ratio8.416+21%6.6525.787+15%5.269+26%4.960+34%6.897-4%
Pe Ratio27.285+21%21.56522.561-4%23.981-10%20.477+5%21.182+2%
Price Per Share49.180+21%38.87030.390+28%22.513+73%21.388+82%17.783+119%
Price To Free Cash Flow Ratio18.618+21%14.71549.716-70%16.661-12%22.448-34%14.030+5%
Price To Total Gains Ratio126.233+21%99.76975.201+33%55.493+80%63.052+58%65.428+52%
Quick Ratio--2.3993.073-22%3.289-27%5.591-57%4.845-50%
Return On Assets--0.0630.053+19%0.042+51%0.054+17%0.076-17%
Return On Equity--0.0770.064+20%0.051+51%0.062+25%0.090-14%
Total Gains Per Share--0.3900.405-4%0.002+17712%0.139+180%0.183+113%
Usd Book Value--638831524.738572408636.080+12%478677145.982+33%486235654.864+31%377231916.597+69%
Usd Book Value Change Per Share--0.4070.423-4%0.002+17712%0.145+180%0.191+113%
Usd Book Value Per Share--6.0975.463+12%4.495+36%4.439+37%3.474+75%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--4103934065.5463200649133.449+28%2392319640.291+72%2354027743.900+74%1942714450.583+111%
Usd Eps--0.4700.353+33%0.252+87%0.276+71%0.257+83%
Usd Free Cash Flow--72193607.26535650556.060+103%38592290.057+87%35083859.143+106%21927411.964+229%
Usd Free Cash Flow Per Share--0.6890.340+103%0.364+89%0.338+104%0.338+104%
Usd Free Cash Flow To Equity Per Share--0.4880.285+71%0.336+45%0.171+185%0.171+185%
Usd Market Cap5376467517.300+21%4249355274.4503322302721.650+28%2493620589.211+70%2427061496.595+75%1999605266.095+113%
Usd Price Per Share51.314+21%40.55731.709+28%23.490+73%22.316+82%18.555+119%
Usd Profit--49262044.20036993225.300+33%23838038.100+107%29524307.250+67%27384489.488+80%
Usd Revenue--190468496.400163958571.750+16%117389282.100+62%113998232.100+67%92535917.981+106%
Usd Total Gains Per Share--0.4070.423-4%0.002+17712%0.145+180%0.191+113%
 EOD+4 -4MRQTTM+25 -10YOY+29 -75Y+26 -1010Y+23 -13

3.3 Fundamental Score

Let's check the fundamental score of Corcept Therapeutics Incorporated based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1527.285
Price to Book Ratio (EOD)Between0-18.416
Net Profit Margin (MRQ)Greater than00.259
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.399
Current Ratio (MRQ)Greater than13.700
Debt to Asset Ratio (MRQ)Less than10.185
Debt to Equity Ratio (MRQ)Less than10.228
Return on Equity (MRQ)Greater than0.150.077
Return on Assets (MRQ)Greater than0.050.063
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Corcept Therapeutics Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.436
Ma 20Greater thanMa 5054.407
Ma 50Greater thanMa 10050.104
Ma 100Greater thanMa 20042.195
OpenGreater thanClose48.520
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Fundamental data was last updated by Penke on 2024-12-01 20:01:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Corcept earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • A Net Profit Margin of 25.9% means that €0.26 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Corcept Therapeutics Incorporated:

  • The MRQ is 25.9%. The company is making a huge profit. +2
  • The TTM is 22.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ25.9%TTM22.4%+3.5%
TTM22.4%YOY20.0%+2.4%
TTM22.4%5Y26.5%-4.1%
5Y26.5%10Y32.1%-5.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.9%-109.0%+134.9%
TTM22.4%-220.8%+243.2%
YOY20.0%-207.5%+227.5%
5Y26.5%-350.0%+376.5%
10Y32.1%-473.2%+505.3%
4.3.1.2. Return on Assets

Shows how efficient Corcept is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • 6.3% Return on Assets means that Corcept generated €0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Corcept Therapeutics Incorporated:

  • The MRQ is 6.3%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 5.3%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ6.3%TTM5.3%+1.0%
TTM5.3%YOY4.2%+1.1%
TTM5.3%5Y5.4%-0.1%
5Y5.4%10Y7.6%-2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3%-11.6%+17.9%
TTM5.3%-11.9%+17.2%
YOY4.2%-11.2%+15.4%
5Y5.4%-12.6%+18.0%
10Y7.6%-14.2%+21.8%
4.3.1.3. Return on Equity

Shows how efficient Corcept is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • 7.7% Return on Equity means Corcept generated €0.08 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Corcept Therapeutics Incorporated:

  • The MRQ is 7.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 6.4%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ7.7%TTM6.4%+1.3%
TTM6.4%YOY5.1%+1.3%
TTM6.4%5Y6.2%+0.3%
5Y6.2%10Y9.0%-2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.7%-14.3%+22.0%
TTM6.4%-15.9%+22.3%
YOY5.1%-14.7%+19.8%
5Y6.2%-18.5%+24.7%
10Y9.0%-19.2%+28.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Corcept Therapeutics Incorporated.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Corcept is operating .

  • Measures how much profit Corcept makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY11.8%-11.8%
TTM-5Y22.9%-22.9%
5Y22.9%10Y26.9%-4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--208.0%+208.0%
TTM--316.8%+316.8%
YOY11.8%-216.9%+228.7%
5Y22.9%-379.8%+402.7%
10Y26.9%-480.9%+507.8%
4.3.2.2. Operating Ratio

Measures how efficient Corcept is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.76 means that the operating costs are €0.76 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.760. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.789. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.760TTM0.789-0.028
TTM0.789YOY0.798-0.009
TTM0.7895Y0.722+0.067
5Y0.72210Y0.661+0.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7602.284-1.524
TTM0.7893.244-2.455
YOY0.7983.262-2.464
5Y0.7224.764-4.042
10Y0.6616.437-5.776
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Corcept Therapeutics Incorporated.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Corcept is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.70 means the company has €3.70 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 3.700. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.708. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.700TTM4.708-1.009
TTM4.708YOY5.462-0.753
TTM4.7085Y7.376-2.667
5Y7.37610Y6.589+0.787
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7003.569+0.131
TTM4.7083.865+0.843
YOY5.4624.644+0.818
5Y7.3765.968+1.408
10Y6.5896.209+0.380
4.4.3.2. Quick Ratio

Measures if Corcept is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • A Quick Ratio of 2.40 means the company can pay off €2.40 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 2.399. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.073. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.399TTM3.073-0.674
TTM3.073YOY3.289-0.217
TTM3.0735Y5.591-2.519
5Y5.59110Y4.845+0.747
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3993.086-0.687
TTM3.0733.384-0.311
YOY3.2894.304-1.015
5Y5.5915.954-0.363
10Y4.8456.436-1.591
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Corcept Therapeutics Incorporated.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Corcept assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Corcept to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.19 means that Corcept assets are financed with 18.5% credit (debt) and the remaining percentage (100% - 18.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.185. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.175. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.185TTM0.175+0.010
TTM0.175YOY0.1750.000
TTM0.1755Y0.127+0.048
5Y0.12710Y0.145-0.018
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1850.346-0.161
TTM0.1750.346-0.171
YOY0.1750.311-0.136
5Y0.1270.365-0.238
10Y0.1450.383-0.238
4.5.4.2. Debt to Equity Ratio

Measures if Corcept is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • A Debt to Equity ratio of 22.8% means that company has €0.23 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.228. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.212. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.228TTM0.212+0.015
TTM0.212YOY0.215-0.003
TTM0.2125Y0.148+0.064
5Y0.14810Y0.180-0.032
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2280.393-0.165
TTM0.2120.432-0.220
YOY0.2150.387-0.172
5Y0.1480.453-0.305
10Y0.1800.498-0.318
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Corcept generates.

  • Above 15 is considered overpriced but always compare Corcept to the Biotechnology industry mean.
  • A PE ratio of 21.57 means the investor is paying €21.57 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Corcept Therapeutics Incorporated:

  • The EOD is 27.285. Based on the earnings, the company is overpriced. -1
  • The MRQ is 21.565. Based on the earnings, the company is fair priced.
  • The TTM is 22.561. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD27.285MRQ21.565+5.720
MRQ21.565TTM22.561-0.996
TTM22.561YOY23.981-1.420
TTM22.5615Y20.477+2.084
5Y20.47710Y21.182-0.706
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD27.285-2.088+29.373
MRQ21.565-2.565+24.130
TTM22.561-3.166+25.727
YOY23.981-3.244+27.225
5Y20.477-6.006+26.483
10Y21.182-6.718+27.900
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Corcept Therapeutics Incorporated:

  • The EOD is 18.618. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 14.715. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 49.716. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD18.618MRQ14.715+3.903
MRQ14.715TTM49.716-35.001
TTM49.716YOY16.661+33.055
TTM49.7165Y22.448+27.268
5Y22.44810Y14.030+8.418
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD18.618-2.720+21.338
MRQ14.715-3.295+18.010
TTM49.716-3.674+53.390
YOY16.661-4.477+21.138
5Y22.448-8.054+30.502
10Y14.030-9.225+23.255
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Corcept is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.65 means the investor is paying €6.65 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Corcept Therapeutics Incorporated:

  • The EOD is 8.416. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.652. Based on the equity, the company is overpriced. -1
  • The TTM is 5.787. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD8.416MRQ6.652+1.764
MRQ6.652TTM5.787+0.865
TTM5.787YOY5.269+0.518
TTM5.7875Y4.960+0.827
5Y4.96010Y6.897-1.936
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.4161.866+6.550
MRQ6.6522.055+4.597
TTM5.7872.392+3.395
YOY5.2692.453+2.816
5Y4.9603.716+1.244
10Y6.8974.373+2.524
4.6.2. Total Gains per Share

2.4. Latest News of Corcept Therapeutics Incorporated

Does Corcept Therapeutics Incorporated still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Corcept Therapeutics Incorporated to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2024-12-11
21:06
NewAmsterdam Pharma Stock Hits 90-Plus RS RatingRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets784,257
Total Liabilities145,422
Total Stockholder Equity638,835
 As reported
Total Liabilities 145,422
Total Stockholder Equity+ 638,835
Total Assets = 784,257

Assets

Total Assets784,257
Total Current Assets466,978
Long-term Assets317,279
Total Current Assets
Cash And Cash Equivalents 137,289
Short-term Investments 243,047
Net Receivables 59,717
Inventory 8,050
Other Current Assets 4,580
Total Current Assets  (as reported)466,978
Total Current Assets  (calculated)452,683
+/- 14,295
Long-term Assets
Property Plant Equipment 8,433
Long Term Investments 167,310
Long-term Assets Other 14,737
Long-term Assets  (as reported)317,279
Long-term Assets  (calculated)190,480
+/- 126,799

Liabilities & Shareholders' Equity

Total Current Liabilities126,216
Long-term Liabilities19,206
Total Stockholder Equity638,835
Total Current Liabilities
Accounts payable 18,584
Other Current Liabilities 7,302
Total Current Liabilities  (as reported)126,216
Total Current Liabilities  (calculated)25,886
+/- 100,330
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt6,791
Long-term Liabilities  (as reported)19,206
Long-term Liabilities  (calculated)6,791
+/- 12,415
Total Stockholder Equity
Retained Earnings 512,989
Total Stockholder Equity (as reported)638,835
Total Stockholder Equity (calculated)512,989
+/- 125,846
Other
Capital Stock135
Common Stock Shares Outstanding 104,703
Net Invested Capital 638,835
Net Working Capital 340,762
Property Plant and Equipment Gross 8,433



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
68,753
75,339
86,537
110,672
220,537
242,976
274,382
299,751
311,694
320,212
328,679
367,022
412,312
445,494
497,823
534,125
571,731
552,398
568,480
585,399
423,756
468,123
496,364
533,255
583,430
617,848
524,625
594,022
621,517
655,935
714,555
784,257
784,257714,555655,935621,517594,022524,625617,848583,430533,255496,364468,123423,756585,399568,480552,398571,731534,125497,823445,494412,312367,022328,679320,212311,694299,751274,382242,976220,537110,67286,53775,33968,753
   > Total Current Assets 
65,689
66,675
81,285
93,942
124,185
150,823
197,175
224,191
236,820
216,864
232,655
267,310
307,358
344,776
438,333
463,493
478,501
409,624
411,270
401,900
266,463
388,220
419,045
452,402
499,253
533,893
432,588
431,527
458,636
503,367
560,846
466,978
466,978560,846503,367458,636431,527432,588533,893499,253452,402419,045388,220266,463401,900411,270409,624478,501463,493438,333344,776307,358267,310232,655216,864236,820224,191197,175150,823124,18593,94281,28566,67565,689
       Cash And Cash Equivalents 
51,536
37,976
33,623
31,060
31,062
33,121
31,165
33,894
41,625
49,650
58,141
44,948
31,269
84,477
58,523
30,560
76,190
52,381
95,430
94,688
77,617
61,862
35,346
50,243
436,619
299,942
172,377
111,800
135,551
149,750
128,588
137,289
137,289128,588149,750135,551111,800172,377299,942436,61950,24335,34661,86277,61794,68895,43052,38176,19030,56058,52384,47731,26944,94858,14149,65041,62533,89431,16533,12131,06231,06033,62337,97651,536
       Short-term Investments 
0
14,798
32,542
44,096
57,682
92,241
128,780
161,300
165,135
137,255
143,396
186,697
244,693
222,838
346,835
398,233
364,506
320,578
274,552
266,643
145,918
283,665
334,740
346,019
365,343
165,115
190,885
243,425
232,670
261,011
344,568
243,047
243,047344,568261,011232,670243,425190,885165,115365,343346,019334,740283,665145,918266,643274,552320,578364,506398,233346,835222,838244,693186,697143,396137,255165,135161,300128,78092,24157,68244,09632,54214,7980
       Net Receivables 
9,860
9,214
9,504
11,872
15,300
17,261
28,704
19,360
17,588
19,218
19,774
22,405
19,928
26,684
22,725
25,357
27,498
23,900
29,020
27,908
29,025
28,178
29,864
30,314
46,857
32,557
47,153
49,926
41,123
61,518
53,837
59,717
59,71753,83761,51841,12349,92647,15332,55746,85730,31429,86428,17829,02527,90829,02023,90027,49825,35722,72526,68419,92822,40519,77419,21817,58819,36028,70417,26115,30011,8729,5049,2149,860
       Inventory 
2,329
2,888
3,089
3,828
4,576
4,876
4,947
5,362
4,732
5,000
5,142
5,462
5,424
5,084
4,927
4,817
4,910
4,948
4,669
4,994
4,988
5,079
5,437
6,046
6,100
6,409
6,915
7,513
7,730
7,190
8,350
8,050
8,0508,3507,1907,7307,5136,9156,4096,1006,0465,4375,0794,9884,9944,6694,9484,9104,8174,9275,0845,4245,4625,1425,0004,7325,3624,9474,8764,5763,8283,0892,8882,329
       Other Current Assets 
1,964
1,799
2,527
3,086
12,896
3,324
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,424
15,870
15,858
20,163
27,562
18,356
9,126
4,580
4,5809,12618,35627,56220,16315,85815,87016,4240000000000000000003,32412,8963,0862,5271,7991,964
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
103,348
96,024
99,712
104,954
100,718
59,490
70,632
93,230
142,774
157,210
183,499
157,293
79,903
77,319
80,853
84,723
83,955
92,037
162,495
162,881
152,568
153,709
317,279
317,279153,709152,568162,881162,49592,03783,95584,72380,85377,31979,903157,293183,499157,210142,77493,23070,63259,490100,718104,95499,71296,024103,348000000000
       Property Plant Equipment 
3,040
4,122
499
553
518
577
552
540
655
2,390
2,283
1,969
4,496
3,962
4,091
4,304
4,184
3,501
2,938
2,248
1,516
3,542
3,126
2,508
1,143
1,036
648
480
315
188
7,156
8,433
8,4337,1561883154806481,0361,1432,5083,1263,5421,5162,2482,9383,5014,1844,3044,0913,9624,4961,9692,2832,3906555405525775185534994,1223,040
       Long Term Investments 
0
4,493
1,494
1,508
15,281
15,010
0
1,481
0
28,842
24,165
35,250
39,352
41,690
4,200
15,425
36,196
81,834
101,657
133,845
112,277
22,566
11,890
4,895
4,947
0
0
59,621
57,176
40,276
19,315
167,310
167,31019,31540,27657,17659,621004,9474,89511,89022,566112,277133,845101,65781,83436,19615,4254,20041,69039,35235,25024,16528,84201,481015,01015,2811,5081,4944,4930
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
10,435
12,876
11,689
15,429
14,504
15,729
17,085
21,247
20,414
18,874
17,765
16,045
16,082
13,812
16,108
22,115
14,920
13,175
15,292
14,785
14,234
15,390
14,737
14,73715,39014,23414,78515,29213,17514,92022,11516,10813,81216,08216,04517,76518,87420,41421,24717,08515,72914,50415,42911,68912,87610,435000000000
> Total Liabilities 
27,374
25,759
20,392
24,370
29,569
27,749
30,873
40,206
35,812
34,457
30,626
32,646
41,130
36,005
44,125
44,445
48,393
41,596
45,805
45,170
47,950
60,312
54,038
59,891
81,588
88,264
103,011
132,343
114,812
108,071
118,312
145,422
145,422118,312108,071114,812132,343103,01188,26481,58859,89154,03860,31247,95045,17045,80541,59648,39344,44544,12536,00541,13032,64630,62634,45735,81240,20630,87327,74929,56924,37020,39225,75927,374
   > Total Current Liabilities 
27,374
25,759
20,392
24,370
29,569
27,749
30,873
40,206
35,573
34,218
30,381
32,396
38,841
34,075
42,243
43,048
47,494
40,601
45,402
44,757
47,541
57,244
49,057
53,068
72,491
78,865
93,059
121,873
104,505
97,202
100,750
126,216
126,216100,75097,202104,505121,87393,05978,86572,49153,06849,05757,24447,54144,75745,40240,60147,49443,04842,24334,07538,84132,39630,38134,21835,57340,20630,87327,74929,56924,37020,39225,75927,374
       Short-term Debt 
14,664
10,107
4,573
0
0
0
0
0
0
1,521
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001,5210000004,57310,10714,664
       Short Long Term Debt 
14,664
10,107
4,573
0
0
0
0
0
0
1,521
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001,5210000004,57310,10714,664
       Accounts payable 
12,710
15,652
2,082
6,226
8,579
7,850
6,365
13,922
8,266
9,330
7,026
5,937
7,537
4,976
6,304
6,510
10,554
6,969
9,216
6,558
6,908
9,269
8,246
8,178
11,976
11,216
7,976
16,710
17,396
12,557
19,484
18,584
18,58419,48412,55717,39616,7107,97611,21611,9768,1788,2469,2696,9086,5589,2166,96910,5546,5106,3044,9767,5375,9377,0269,3308,26613,9226,3657,8508,5796,2262,08215,65212,710
       Other Current Liabilities 
0
0
0
0
20,990
728
687
1,583
1,542
450
469
552
751
4,473
5,698
249
202
314
977
518
809
12,000
623
863
872
1,220
34,126
44,960
654
0
5,296
7,302
7,3025,296065444,96034,1261,22087286362312,0008095189773142022495,6984,4737515524694501,5421,58368772820,9900000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
239
245
250
2,289
1,930
1,882
1,397
899
995
403
413
409
3,068
4,981
6,823
9,097
9,399
9,952
10,470
10,307
10,869
17,562
19,206
19,20617,56210,86910,30710,4709,9529,3999,0976,8234,9813,0684094134039958991,3971,8821,9302,289250245239000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
239
239
245
250
386
389
396
400
398
995
403
413
409
2,516
4,981
6,823
9,097
0
0
10,470
0
0
0
0
000010,470009,0976,8234,9812,51640941340399539840039638938625024523923900000000
> Total Stockholder Equity
41,379
49,580
66,145
86,302
190,968
215,227
243,509
259,545
275,882
285,755
298,053
334,376
371,182
409,489
453,698
489,680
523,338
510,802
522,675
540,229
375,806
407,811
442,326
473,364
501,842
529,584
421,614
461,679
506,705
547,864
596,243
638,835
638,835596,243547,864506,705461,679421,614529,584501,842473,364442,326407,811375,806540,229522,675510,802523,338489,680453,698409,489371,182334,376298,053285,755275,882259,545243,509215,227190,96886,30266,14549,58041,379
   Common Stock
113
113
113
114
115
115
116
116
117
118
118
119
120
120
121
121
122
124
125
126
127
128
128
130
131
0
0
133
0
0
0
0
000013300131130128128127126125124122121121120120119118118117116116115115114113113113
   Retained Earnings Total Equity00000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000
   Other Stockholders Equity 
0
-12
-17
-14
-75
-152
-127
-77
-70
94
321
314
261
310
840
577
415
249
215
115
-227
-1,351
-2,141
-2,381
-869
0
0
-234
0
0
0
0
0000-23400-869-2,381-2,141-1,351-22711521524941557784031026131432194-70-77-127-152-75-14-17-120



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in EUR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue482,375
Cost of Revenue-6,481
Gross Profit475,894475,894
 
Operating Income (+$)
Gross Profit475,894
Operating Expense-375,093
Operating Income107,282100,801
 
Operating Expense (+$)
Research Development184,353
Selling General Administrative184,259
Selling And Marketing Expenses-
Operating Expense375,093368,612
 
Net Interest Income (+$)
Interest Income17,275
Interest Expense--
Other Finance Cost-0
Net Interest Income17,275
 
Pretax Income (+$)
Operating Income107,282
Net Interest Income17,275
Other Non-Operating Income Expenses-
Income Before Tax (EBT)124,557107,282
EBIT - interestExpense = 0
106,140
106,140
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-124,557
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax124,557
Tax Provision-18,417
Net Income From Continuing Ops106,140106,140
Net Income106,140
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--17,275
 

Technical Analysis of Corcept
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Corcept. The general trend of Corcept is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Corcept's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Corcept Therapeutics Incorporated.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 54.32 < 58.44.

The bearish price targets are: 48.51 > 45.35 > 37.48.

Tweet this
Corcept Therapeutics Incorporated Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Corcept Therapeutics Incorporated. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Corcept Therapeutics Incorporated Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Corcept Therapeutics Incorporated. The current macd is -0.04963558.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Corcept price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Corcept. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Corcept price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Corcept Therapeutics Incorporated Daily Moving Average Convergence/Divergence (MACD) ChartCorcept Therapeutics Incorporated Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Corcept Therapeutics Incorporated. The current adx is 28.16.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Corcept shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Corcept Therapeutics Incorporated Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Corcept Therapeutics Incorporated. The current sar is 55.11.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Corcept Therapeutics Incorporated Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Corcept Therapeutics Incorporated. The current rsi is 40.44. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Corcept Therapeutics Incorporated Daily Relative Strength Index (RSI) ChartCorcept Therapeutics Incorporated Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Corcept Therapeutics Incorporated. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Corcept price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Corcept Therapeutics Incorporated Daily Stochastic Oscillator ChartCorcept Therapeutics Incorporated Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Corcept Therapeutics Incorporated. The current cci is -187.18168813.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Corcept Therapeutics Incorporated Daily Commodity Channel Index (CCI) ChartCorcept Therapeutics Incorporated Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Corcept Therapeutics Incorporated. The current cmo is -35.97339019.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Corcept Therapeutics Incorporated Daily Chande Momentum Oscillator (CMO) ChartCorcept Therapeutics Incorporated Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Corcept Therapeutics Incorporated. The current willr is -93.34677419.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Corcept Therapeutics Incorporated Daily Williams %R ChartCorcept Therapeutics Incorporated Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Corcept Therapeutics Incorporated.

Corcept Therapeutics Incorporated Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Corcept Therapeutics Incorporated. The current atr is 1.42898063.

Corcept Therapeutics Incorporated Daily Average True Range (ATR) ChartCorcept Therapeutics Incorporated Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Corcept Therapeutics Incorporated. The current obv is -5,332.

Corcept Therapeutics Incorporated Daily On-Balance Volume (OBV) ChartCorcept Therapeutics Incorporated Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Corcept Therapeutics Incorporated. The current mfi is 38.08.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Corcept Therapeutics Incorporated Daily Money Flow Index (MFI) ChartCorcept Therapeutics Incorporated Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Corcept Therapeutics Incorporated.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-06 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-07 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-15 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-16 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-23 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-29 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-30 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-02 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-03 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-04 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-05 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-10 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-11 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-13 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-26 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-01 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-03 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-10-14 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-15 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-17 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-21 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-24 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-25 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-01 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-04 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-05 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-06 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-12 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-11-14 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-20 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-21 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-22 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-25 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-28 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-29 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-03 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-04 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-05 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-11 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-16 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-19 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Corcept Therapeutics Incorporated Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Corcept Therapeutics Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.436
Ma 20Greater thanMa 5054.407
Ma 50Greater thanMa 10050.104
Ma 100Greater thanMa 20042.195
OpenGreater thanClose48.520
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Corcept with someone you think should read this too:
  • Are you bullish or bearish on Corcept? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Corcept? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Corcept Therapeutics Incorporated

I send you an email if I find something interesting about Corcept Therapeutics Incorporated.


Comments

How you think about this?

Leave a comment

Stay informed about Corcept Therapeutics Incorporated.

Receive notifications about Corcept Therapeutics Incorporated in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.